AdBio Partners Expands Into Asia With The Opening of a Taipei Office

Paris, France and Taipei, Taiwan - November 24, 2026

AdBio Partners, a venture capital firm specialized in early-stage life sciences, today announced the opening of a new office in Taipei, marking the firm's expansion into Asia and establishing Taipei as a new base for its investment and company-building activities alongside its European and Canadian presence.

The move builds on AdBio's strategy of identifying promising science at its earliest stages and partnering with researchers, entrepreneurs and academic institutions to create and finance biotechnology companies developing first- or best-in-class therapeutics. Since its creation in 2016, AdBio has built with its two first funds a portfolio of 30 companies across Europe, attracting significant follow-on investment and syndication from leading venture capital investors and pharmaceutical companies.

"With our Taiwanese team member TsungYen's deep local knowledge, Taiwan was a natural choice for AdBio's first Asia expansion outside Europe and Canada," said Alain Huriez, MD, Founder and Chairman of AdBio Partners. "The combination of outstanding academic science, experienced drug development talent and a highly dynamic public market makes Taiwan a strong fit with our model and the best base for our Asian operations. By establishing a team on the ground, we can engage with researchers and founders at the earliest stages of company creation and connect them to AdBio's international network of investors, entrepreneurs and pharmaceutical partners."

AdBio's Asia expansion coincides with its earlier expansion in Canada and the launch of its third fund, which is backed by Taiwan's National Development Fund NDF, a leading Taiwan-based sovereign investor that provides both capital and in-depth local support in the life sciences sector and among other LPs, the European Investment Fund (EIF) as well as The National Seed Fund 3, managed on behalf of the French government by Bpifrance as part of France 2030. The partnership reflects a shared ambition to support the creation and growth of biotechnology companies in Taiwan and broaden their access to global capital and specialist expertise.

"By investing in AdBio Partners third fund, NDF is backing a specialized investment firm with a recognized track record in building and supporting high-potential biotechnology companies. We are particularly pleased that this commitment facilitates the opening of AdBio Partners Taipei office. This local presence will create greater opportunities for collaboration among researchers, entrepreneurs and investors cross-linking between the West and the East, while helping foster the next generation of innovative life sciences companies in Taiwan," said Dr. Ting-An Wang, Executive Secretary, NDF.

AdBio's Taiwan activities will be led by **TsungYen Wu, PhD, Operating Principal – Head of APAC, and ChengRu Lauren Chen, Senior Analyst,** in collaboration with the firm's broader investment team and Venture Partners. Through AdBio Fund III, the Taipei team aims to build a durable bridge between Taiwan, Canada and Europe for the creation and financing of early-stage biotechnology companies.

About AdBio Partners

Founded in Paris in 2016, AdBio Partners is a venture capital firm specialized in early-stage life sciences. Its investment strategy combines seed financing with hands-on company building, working closely with scientific founders, entrepreneurs and leading research institutions to create and develop biotechnology companies focused on innovative therapeutics. AdBio Partners operates from Paris, Barcelona, Montreal and Taipei. For more information, visit www.adbio.partners or follow us on LinkedIn.

About National Development Fund NDF

The National Development Fund (NDF), Executive Yuan is a cornerstone of Taiwan's economic progress, fulfilling its mission through a strategic state-backed investment model established in 1973. Since then, the NDF has catalyzed Taiwan's industrial evolution by mobilizing national resources to foster innovation, research, and sustainable growth.

With net assets exceeding NT$2.93 trillion (approx. US$89 billion), the NDF supports directly and indirectly thousands of enterprises through venture capital, direct equity, and specialized loan financing based on the belief that strategic capital drives both economic competitiveness and long-term societal development. Through targeted initiatives—ranging from its Business Angel Investment Program to strategic funds in AI, net-zero transition, and industrial transformation—the NDF continues to accelerate private-sector investment across Taiwan. For more information, visit: www.df.gov.tw.

Press contacts

AdBio Partners

TsungYen Wu
yenwu@adbio.partners

National Development Fund NDF
df@df.gov.tw